Prostate cancer is the most common cancer in men, yet relatively few patients die from the disease. Distinguishing aggressive tumors – which require treatment – from indolent ones – which can be monitored through active surveillance – remains a key challenge in prostate cancer disease management. Learn more. 

Cellanyx has developed a LDT (laboratory developed test) that uniquely analyzes live tumor cell behavior to stratify the risk of prostate tumor aggressiveness in the most challenging group of men – individuals with low and intermediate grade prostate cancer). It is poised to begin a prospective clinical utility study to support its commercial introduction. Learn more. 

Tumor cells behave differently than normal cells. Cellanyx’s platform analyzes biomarkers in live cells that are hallmarks cancer to generate objective, quantitative and predictive measures of adverse pathology to aggressive disease risk. The tests add great precision to traditional pathology tests and are distinct from genetic tests, which infer risk based on a small set of genes.

Learn more. 

Cellanyx has a pipeline of LDT tests for other solid tumors in earlier stages of development including tests for breast, kidney, bladder and non-small cell lung cancers. The most advanced of these tests is for Stage 0 breast cancer.

Learn more